Century TherapeuticsIPSC
About: Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Employees: 165
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
10% more funds holding
Funds holding: 61 [Q2] → 67 (+6) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0.95% less ownership
Funds ownership: 47.75% [Q2] → 46.8% (-0.95%) [Q3]
12% less call options, than puts
Call options by funds: $15K | Put options by funds: $17K
34% less capital invested
Capital invested by funds: $103M [Q2] → $67.8M (-$35.1M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Chardan Capital Geulah Livshits 17% 1-year accuracy 8 / 48 met price target | 900%upside $11 | Buy Maintained | 7 Nov 2024 |
HC Wainwright & Co. Mitchell Kapoor 25% 1-year accuracy 41 / 164 met price target | 355%upside $5 | Buy Maintained | 6 Nov 2024 |
Financial journalist opinion
